In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates

Barry, Arthur L.; Brown, S D; Novick, William J.

doi:10.1128/aac.39.10.2193

Cited by 25 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, new therapeutic compounds must be evaluated. In our study, the MIC 90 s of meropenem, imipenem, ceftriaxone, and vancomycin of penicillin-sensitive, -intermediate, and -resistant pneumococci were consistent with those reported elsewhere (3,27). On the basis of the MICs, imipenem was the most active ␤-lactam agent.…”

supporting

confidence: 91%

Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis

Fitoussi

Doit

Bénali

et al. 1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The activities of meropenem, imipenem, ceftriaxone, and vancomycin were evaluated against 80 penicillinsusceptible and-resistant Streptococcus pneumoniae strains. Meropenem, imipenem, ceftriaxone, and vancomycin MICs at which 90% of the isolates are inhibited were 0.5, 0.25, 1, and 0.25 g/ml, respectively. Against penicillin-resistant strains, the best killing activity at cerebrospinal fluid concentrations was obtained with imipenem and ceftriaxone-vancomycin. However, while the killing activity of imipenem was significantly greater than that of meropenem, no significant difference was observed between the activities of meropenem and ceftriaxone-vancomycin.

show abstract

supporting

confidence: 91%

Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis

Fitoussi

Doit

Bénali

et al. 1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The clinical efficacy of a single intramuscular injection of 50 mg of CRO per kg of body weight in pediatric patients with uncomplicated otitis media is equivalent to those of standard oral 7-or 10-day amoxicillin (22,36), 10-day amoxicillin-clavulanate (37), and 10-day trimethoprimsulfamethoxazole (4) therapy. The recent emergence of clinical cephalosporin-resistant S. pneumoniae strains, revealed by treatment failures in patients with pneumococcal meningitis (10-12, 17, 24, 31), although initially considered an epiphenomenon (15), now appears to be a continuum in penicillinbinding protein alterations in penicillin-resistant strains (5). This extension of resistance must be taken into account in the assessment of CRO therapy.…”

mentioning

confidence: 99%

Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae

Barry

Muffat-Joly

Bauchet

et al. 1996

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We used a gerbil model of otitis media to assess the efficacy of single-dose ceftriaxone against three Streptococcus pneumoniae strains highly resistant to penicillin (MICs, 4 to 8 micrograms/ml) and with various susceptibilities to ceftriaxone (MICs, 0.5, 4, and 8 micrograms/ml). Middle ear infection was induced by bilateral transbullar challenge with 10(7) bacteria per ear. Antibiotic treatment was administered subcutaneously at 2 h postinfection. Infection status was checked 2 days later by counting the bacteria in middle ear and cerebrospinal fluid samples. With the cefriaxone-susceptible strain (MIC, 0.5 microgram/ml), we tested doses of 5 to 100 mg/kg of body weight. With a dose of 50 mg/kg, treatment outcome was equivalent to that with amoxicillin, which was used as a reference (25 mg/kg, two injections); no bacteria were recovered from 82% of the middle ear samples, and the rate of cerebrospinal fluid culture positivity was significantly reduced to 6%, relative to 59% for the untreated controls. Similar efficacy was obtained with a dose of 100 mg/kg against the two ceftriaxone-resistant strains. Pharmacokinetic study indicates that the values of the parameters in plasma after the administration of a dose of 100 mg/kg (peak level of total drug, 268 +/- 33 micrograms/ml; elimination half-life, 0.8 h; area under concentration-time curve, 488 micrograms.h.ml-1) were still suboptimal compared with the values of the parameters measured in pediatric patients after intravenous or intramuscular administration of a dose of 50 mg/kg. Our results indicate the efficacy of ceftriaxone against experimental cephalosporin-resistant pneumococcal otitis and provide a basis for the clinical use of single-dose ceftriaxone against pneumococcal otitis media.

show abstract

“…Additionally, the reported ceftazidime resistance is very interesting given the pan-susceptibility to all simple b-lactams, which requires further investigation. Similar instances of streptococcal strains that are penicillin-susceptible and resistant to ceftazidime have already been reported (Barry et al, 1995), and ceftazidime resistance has been attributed to mutations in several bla CTX-M determinants (Welsh et al, 2005).…”

Section: Discussionmentioning

confidence: 64%

Streptococcus constellatus-associated pyoderma in a dog

Martino

Nizza

Martinis

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

This report describes a case of chronic and deep pyodermitis in a 4-year-old male dog with a 3-month skin problems history that had been treated unsuccessfully with fluoroquinolone therapy, prescribed by a private medical veterinary practice, without an early diagnosis. Microbiological examination and antimicrobial susceptibility testing were performed in our laboratory (Faculty of Veterinary Medicine) and a diagnosis of Streptococcus constellatusassociated pyoderma in the dog was made. A new antimicrobial treatment, with tetracyclines, was designed after the definitive diagnosis and antimicrobial susceptibility testing performed by the Kirby-Bauer disc diffusion method. The dog remained free of clinical illness at completion of therapy. To our knowledge, this is the first case of a canine pyoderma caused by S. constellatus, a commensal organism which may also cause pyogenic infections. Furthermore, this study confirms that a fluoroquinolone represents a poor empirical choice for initial therapy of canine pyoderma.

show abstract

In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates

Cited by 25 publications

References 14 publications

Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis

Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis

Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae

Streptococcus constellatus-associated pyoderma in a dog

Contact Info

Product

Resources

About